• Cellectis received FDA RMAT designation for lasme-cel, an off-the-shelf CD22 CAR-T, supporting its pivotal Phase 2 BALLI-01 program in relapsed or refractory B-cell ALL.
• The designation follows Phase 1 BALLI-01 results that showed encouraging activity with a manageable safety profile, without disclosing detailed metrics.
• Final Phase 1 results will be presented on June 13 at the 2026 European Hematology Association congress.
• The pivotal Phase 2 study is open for enrollment, positioning lasme-cel as a potential accelerated regulatory candidate in a high-need leukemia setting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.